BiotechTube
Home/Pipeline/ALMANAC Study

ALMANAC Study

Multi-Cancer Early Detection

ResearchActive

Key Facts

Indication
Multi-Cancer Early Detection
Phase
Research
Status
Active
Company
Guardant Health

About Guardant Health

Guardant Health's mission is to transform cancer care by unlocking critical insights from a simple blood draw, shifting the paradigm from reactive to proactive, data-driven management. The company has achieved significant clinical adoption with over 500,000 commercial tests performed by more than 12,000 oncologists and secured FDA approval for its colorectal cancer screening test, Guardant Shield. Its strategy is built on a three-pillar business model spanning Clinical diagnostics, Biopharma solutions, and a high-growth Screening franchise, all powered by its proprietary liquid biopsy and multi-omic platform, Guardant Infinity.

View full company profile

Therapeutic Areas

OncologyCancer Screening

Other Multi-Cancer Early Detection Drugs

DrugCompanyPhase
Ausel Cancer TestAusel Cancer InnovationPre-clinical
GAGome for MCEDElyptaClinical Validation
Rivela MCED TestEXOSOMICSPre-clinical
CancerGuard™Exact SciencesPivotal Studies
PATHFINDER 2GRAILInterventional Study
REACH/Galleri-Medicare StudyGRAILProspective Cohort Study
REFLECTION StudyGRAILObservational Study
SUMMIT StudyGRAILObservational Cohort Study
PATHFINDER StudyGRAILInterventional Study
MCED TestMainz BiomedResearch Collaboration